For OSE, partnerships and out-licensing deals with global pharmaceutical companies represent ways to rapidly advance the clinical development of its product candidates. Selective partnerships represent a key piece of OSE’s business model that can contribute significantly to the cash flow needed to continue discovering and developing new targets and therapeutic candidates.

OSE is actively pursuing a partnership strategy with potential pharmaceutical partners.

Existing partnerships signed with premier international pharmaceutical companies for the clinical development of the Company’s most advanced and innovative programs include the following:

• Boehringer Ingelheim (April 2018): A global license and collaboration agreement to develop BI 765063 (OSE-172) in multiple cancer indications.
• Servier (December 2016): A license option agreement covering development and commercialization of OSE-127 targeting both ulcerative colitis and Sjögren’s syndrome.
• Chong Kun Dang Pharmaceutical Corporation(CKD) (November 2019):  A licensing deal for potential registration and commercialization of Tedopi® in Korea.
• Veloxis Pharmaceuticals (April 2021): A global license agreement granting Veloxis worldwide rights to develop, manufacture and commercialize FR104 for all transplant indications (in parallel, OSE retains all product rights to develop FR104 in autoimmune diseases).

Each of these agreements includes an initial upfront payment as well as milestone payments and royalties on potential future sales.

Together, existing partnerships represent a potential of up to €1.6 billion of revenue for OSE and additional royalties on future sales, demonstrating our expertise discovering valuable new targets and therapies and validating the high potential of our drug candidates.